Company: SXTPW
Filing Date: 2025-07-16
Form Type: 424B4
Source: 0001213900-25-064472
Chunk: 50

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-16
Form: 424B4
Chunk 50
---
 proceeds as described
above, we intend to invest the net proceeds of this offering in a money market or other interest-bearing account. The amounts and timing of our actual expenditures will depend upon numerous factors, including our sales and marketing and commercialization efforts, demand for our products, our operating costs and the other factors described under “ Risk Factors” in this prospectus and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Accordingly, our management will have flexibility in applying the net proceeds from this offering. An investor will not have the opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use the proceeds.

<div align='center'>25

DIVIDEND POLICY</div>

We have not declared any cash dividends since
inception and we do not anticipate paying any dividends in the foreseeable future. Instead, we anticipate that all of our earnings will
be used to provide working capital, to support our operations, and to finance the growth and development of our business. The payment
of dividends is within the discretion of the Board and will depend on our earnings, capital requirements, financial condition, prospects,
operating results, cash needs, growth plans, applicable Delaware law, which provides that dividends are only payable out of surplus or
current net profits, and other factors our board might deem relevant. There are no restrictions that currently limit our ability to pay
dividends on our common stock other than those generally imposed by applicable state law.

<div align='center'>CAPITALIZATION</div>

The following table sets forth our consolidated
cash and capitalization as of March 31, 2025:

| ● | On an actual basis; and |

| ● | On an as adjusted basis giving effect to the sale of 1,753,314 shares                                                                        
 of common stock and Pre-Funded Warrants to purchase up to 878,264 shares of common stock, and accompanying Series A-1 Warrants to purchase   
 up to an aggregate of 2,631,578 shares of common stock and Series A-2 Warrants to purchase up to an aggregate of 2,631,578 shares of common  
 stock by us in this public offering at a public offering price of $1.90 per share and accompanying warrants and $1.899 per pre-funded        
 warrant and accompanying warrants after deducting estimated placement agent fees and estimated offering expenses payable by us, and assuming 
 exercise in full of the Pre-Funded Warrants offered in this